Drugs that missed the mark in pharma’s last earnings round
Alnylam reported $1.01B in Q2 Amvuttra sales, below consensus, and trimmed 2026 revenue guidance for its transthyretin franchise by $200M to $4.2B-$4.5B, citing normalized second-line demand. The article also notes AbbVie’s Imbruvica Q2 $532M vs ~$533M, Merck’s vaccines slightly below expectations, and Roche’s Vabysmo $1.27B vs consensus.
How this was made
The 30-second read
Why it matters
It ties each company’s underperformance to specific drivers: ALNY guidance cut from demand normalization, ABBV pricing compression and competition, MRK lower U.S. demand amid policy volatility, and RHHBY slower retinal-market growth.
Market read
Traders can use the quantified Q2 misses and guidance revisions to reassess near-term revenue risk and competitive/pricing overhangs in key pharma franchises.
What to watch
Cross-trial comparisons (e.g., Wainua subgroup signals) are limited, and some misses are partially offset by pricing or non-U.S. demand, which can soften the market reaction.
Background
The article reviews multiple pharma franchises that missed or fell short of expectations in the latest earnings round, focusing on why investors are disappointed.
Ticker impact
Alnylam reported $1.01B Amvuttra Q2 sales below consensus and trimmed 2026 franchise revenue guidance by $200M to $4.2B-$4.5B.
Bearish bias for ALNY as investors reprice slower growth and franchise durability.
The article cites a specific Q2 miss, a quantified full-year guidance reduction, and management attribution to post-expansion demand normalization.
AbbVie’s Imbruvica generated $532M Q2 revenue, narrowly missing consensus, with sales down 29.4% YoY amid negotiated Medicare pricing pressure.
Negative-to-neutral read-through for ABBV as BTK competition and IRA-linked pricing weigh on growth.
The article provides a concrete Q2 miss and key drivers (Medicare negotiated price, newer BTK inhibitors), but no new ABBV guidance is stated.
Merck’s Varivax, MMR-II, and ProQuad produced $592M Q2 revenue, about 2.6% below analyst expectations, driven mainly by lower U.S. demand.
Slightly negative bias for MRK near term, but likely limited given the small miss and partial offsets.
The article includes a quantified Q2 shortfall and stated drivers, but does not confirm a policy-driven impact for this quarter.
Market effects
Highlights how pricing policy (IRA/Medicare) and demand normalization can quickly turn blockbuster expectations into guidance risk across pharma.
Primarily U.S.-centric demand and pricing dynamics (Medicare negotiated pricing, U.S. vaccine demand) with some Europe offsets.
Retinal-market growth deceleration and competitive intensity are cross-market themes affecting global ophthalmology sentiment.
Counterpoint
Management confidence and franchise investment plans may limit downside if demand normalization is temporary and peak-sales targets remain intact.
Key entities
- companyAlnylam Pharmaceuticals
Amvuttra franchise sales and guidance were trimmed after a Q2 miss.
- companyAbbVie
Imbruvica faced Medicare negotiated price pressure and competitive erosion.
- companyMerck
Varivax/MMR-II/ProQuad revenue missed expectations mainly due to lower U.S. demand.
- companyRoche
Vabysmo sales missed consensus as retinal-market growth slowed to a new normal.
